Evidence map›Paper›PMID 42058242›Full record

ArticleArchives of Razi Institute2025

Kazeminejad Arezou, Kia Eshrat Beigom, Bagheri-Josheghani Sareh, Fahimfar Noshin, Darabi Enayat, Fakhrieh-Kashan Zohreh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kazeminejad ArezouDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Kia Eshrat BeigomDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Bagheri-Josheghani SarehInfectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Fahimfar NoshinDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Darabi EnayatDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Fakhrieh-Kashan ZohrehDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In individuals with compromised immune systems, strongyloidiasis disease can lead to disseminated infections that can be fatal if diagnosis and treatment are delayed. The human gut is composed of numerous bacteria that play essential roles in the development of acquired immunity, and protection against pathogenic factors. This case-control study was conducted on individuals who were referred to the Diagnostic Laboratory of Strongyloidiasis in the School of Public Health, Tehran University of Medical Sciences. After DNA extraction from fecal samples, the 16SrRNA gene was examined using Real-time PCR. The levels of

Indexed as

BifidobacteriumBifidobacterium bifidumLactobacillus acidophilusStrongyloidiasisAdultAgedCase-Control StudiesFecesFemaleHumansIranMaleMiddle AgedBifidobacterium bifidumLactobacillus acidophilusStrongyloidiasis

Identifiers

PMID42058242
PMCPMC13122410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.